Articles related to Hematology

Explore the latest insights into the complex pathophysiology of steroid-refractory cGVHD and the significant strides made in treatment options, including the impactful roles of ruxolitinib, belumosudil, and ibrutinib in enhancing patient outcomes.

Exa-cel’s success in the CLIMB THAL-111 trial represents a transformative approach to treating β-thalassemia, eliminating dependency on transfusions and underscoring the potential of gene editing in hematological disorders.

The REVIVE trial elucidates rusfertide’s capacity to maintain hematocrit levels below 45% during its 28-week study period, underscoring its potential as a transformative agent in the treatment of polycythemia vera. This efficacy, coupled with a favorable safety profile, marks a significant advancement in therapeutic options for this chronic condition.

For patients with cirrhosis facing venous thromboembolic events, the choice of anticoagulant—be it DOACs or LMWH—demands careful consideration of their unique hemostatic profile, emphasizing the need for personalized treatment strategies.

As healthcare moves forward, it’s crucial to balance quantitative data with the nuanced realities of patient experiences. This article explores the impact of the ‘quantitative fallacy’ on patient care and the importance of clinical judgment.

In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.